Hey man I get where you are coming from, I really do. But if you have followed as many Phase I, II, and III studies as I have, you learn that unfortunately information outside of your typical Phase III double blinded trial can be manipulated or positioned in a more favorable way.
For example take a look at my post that IC referred someone to when I first joined Ihub (thanks for the reminder). It gives survival data on younger patients of close to 3 years. So when data is presented against different study data, patients are excluded, or patients are included, and this differs from historical norms it will certainly peak my interest.
Why were the patients accounted for differently? Why didn't they highlight it? Could this be because of treatment and be positive? Sure it can but those aren't things I'm willing to make assumptions about.
Market Data 
Markets 
AI
